You just read:

Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After Demonstrating Safety and Tolerability in Phase 1 Study

News provided by

Second Genome, Inc.

Dec 19, 2017, 07:00 EST